CA2291839A1 - Conjugated peptide nucleic acids having enhanced cellular uptake - Google Patents

Conjugated peptide nucleic acids having enhanced cellular uptake Download PDF

Info

Publication number
CA2291839A1
CA2291839A1 CA002291839A CA2291839A CA2291839A1 CA 2291839 A1 CA2291839 A1 CA 2291839A1 CA 002291839 A CA002291839 A CA 002291839A CA 2291839 A CA2291839 A CA 2291839A CA 2291839 A1 CA2291839 A1 CA 2291839A1
Authority
CA
Canada
Prior art keywords
naturally
group
amino acid
occurring
side chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002291839A
Other languages
English (en)
French (fr)
Inventor
Peter E. Nielsen
Helle Knudsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2291839A1 publication Critical patent/CA2291839A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C07K14/003—Peptide-nucleic acids (PNAs)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dispersion Chemistry (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CA002291839A 1997-05-28 1998-05-28 Conjugated peptide nucleic acids having enhanced cellular uptake Abandoned CA2291839A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86476597A 1997-05-28 1997-05-28
US08/864,765 1997-05-28
PCT/US1998/010804 WO1998053801A1 (en) 1997-05-28 1998-05-28 Conjugated peptide nucleic acids having enhanced cellular uptake

Publications (1)

Publication Number Publication Date
CA2291839A1 true CA2291839A1 (en) 1998-12-03

Family

ID=25344022

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002291839A Abandoned CA2291839A1 (en) 1997-05-28 1998-05-28 Conjugated peptide nucleic acids having enhanced cellular uptake

Country Status (7)

Country Link
EP (1) EP1003480A4 (de)
JP (1) JP2001501975A (de)
AU (1) AU745309B2 (de)
CA (1) CA2291839A1 (de)
IL (1) IL133087A0 (de)
NZ (1) NZ501289A (de)
WO (1) WO1998053801A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6472209B1 (en) 1997-10-17 2002-10-29 Mayo Foundation For Medical Education And Research Using polyamide nucleic acid oligomers to engender a biological response
US6723560B2 (en) 1998-10-08 2004-04-20 Mayo Foundation For Medical Education And Research Using polyamide nucleic acid oligomers to engender a biological response
US6989270B1 (en) 1997-10-17 2006-01-24 Mayo Foundation For Medical Education And Research Using polyamide nucleic acid oligomers to engender a biological response
DE19909373A1 (de) * 1999-03-03 2000-10-05 Ugichem Neue PNA-Monomere, daraus resultierende PNA-Oligomere und deren Verwendung
DE10038169A1 (de) * 2000-08-04 2002-03-07 November Ag Molekulare Medizin Synthetisches Partikel zur Markierung einer Substanz
AU2003260289A1 (en) * 2002-09-11 2004-04-30 Santaris Pharma A/S Modified pna molecules
JP5645840B2 (ja) 2008-12-02 2014-12-24 株式会社Ｗａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｊａｐａｎ リン原子修飾核酸の合成方法
CN102596204B (zh) 2009-07-06 2016-11-23 波涛生命科学有限公司 新的核酸前药及其使用方法
EP2620428B1 (de) 2010-09-24 2019-05-22 Wave Life Sciences Ltd. Asymmetrische hilfsgruppe
JP6128529B2 (ja) 2011-07-19 2017-05-17 ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． 官能化核酸の合成のための方法
AU2013287630B2 (en) 2012-07-13 2017-05-25 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant
WO2014012081A2 (en) 2012-07-13 2014-01-16 Ontorii, Inc. Chiral control
PL2872485T3 (pl) 2012-07-13 2021-05-31 Wave Life Sciences Ltd. Asymetryczna grupa pomocnicza
WO2015108047A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
EP3095460A4 (de) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chirales nukleinsäureadjuvans mit antiallergischer wirkung und antiallergikum
JPWO2015108048A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
US10160969B2 (en) 2014-01-16 2018-12-25 Wave Life Sciences Ltd. Chiral design
DE102014007158A1 (de) * 2014-05-16 2015-11-19 Ugichem Gmbh Neue Peptid-Nukleinsäuren-Monomere und -Oligomere
UA121863C2 (uk) * 2014-06-24 2020-08-10 Транслейт Байо, Інк. Стереохімічно збагачені композиції для доставки нуклеїнових кислот
AU2020315947A1 (en) * 2019-07-24 2022-03-10 The Trustees Of Columbia University In The City Of New York Methods and compositions for treating cancer using peptide nucleic acid-based agents
CN114315835B (zh) * 2021-11-30 2023-03-03 华南农业大学 一种6-苯甲基腺嘌呤半抗原、人工抗原、抗体及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK51092D0 (da) * 1991-05-24 1992-04-15 Ole Buchardt Oligonucleotid-analoge betegnet pna, monomere synthoner og fremgangsmaade til fremstilling deraf samt anvendelser deraf
US5539082A (en) * 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
US5705333A (en) * 1994-08-05 1998-01-06 The Regents Of The University Of California Peptide-based nucleic acid mimics(PENAMS)
ATE222589T1 (de) * 1994-10-06 2002-09-15 Isis Pharmaceuticals Inc Peptid-nukleinsäure-konjugate
AU4344696A (en) * 1994-12-21 1996-07-10 Novartis Ag Oligonucleotide-dendrimer conjugates
EP0870055B1 (de) * 1995-10-12 2007-05-16 LANSDORP, Peter, M. Verfahren zum nachweis von mehrfachkopien einer wiederholungssequenz in einem nukleinsäuremolekül

Also Published As

Publication number Publication date
IL133087A0 (en) 2001-03-19
EP1003480A1 (de) 2000-05-31
EP1003480A4 (de) 2002-04-17
JP2001501975A (ja) 2001-02-13
NZ501289A (en) 2001-06-29
WO1998053801A1 (en) 1998-12-03
AU7602198A (en) 1998-12-30
AU745309B2 (en) 2002-03-21

Similar Documents

Publication Publication Date Title
US6686442B2 (en) Conjugated peptide nucleic acids having enhanced cellular uptake
AU745309B2 (en) Conjugated peptide nucleic acids having enhanced cellular uptake
EP1709195B1 (de) Zelltransfektionsformulierungen von kleiner interferierender rna, verwandte zusammensetzungen und herstellungsverfahren und verwendung
AU680253B2 (en) Novel peptide nucleic acids
US5777153A (en) Cationic lipids
US20030207804A1 (en) Modified peptide nucleic acids
US6300317B1 (en) Self-assembling polynucleotide delivery system
US5986053A (en) Peptide nucleic acids complexes of two peptide nucleic acid strands and one nucleic acid strand
EP0773950B1 (de) Verknüpfte peptid-nukleinsäuren
EP1074559B1 (de) Peptidnucleinsäuren
JP2538474B2 (ja) 生物学的活性分子の細胞内配達のための陽イオン脂質
US20030073640A1 (en) Novel compositions for the delivery of negatively charged molecules
US7214384B2 (en) Lipid-conjugated polyamide compounds
US20100022016A1 (en) Polyamide nucleic acid derivatives and agents, and processes for preparing them
CA2498772A1 (en) Modified pna molecules
MXPA01013114A (es) Conjugados y metodos para la produccion de los mismos, y su uso poara transportar moleculas a traves de membranas biologicas.
MXPA02009738A (es) Derivados de acido nucleico de peptido con carga negativa, agentes y metodos para su preparacion.

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued